Swedish biotech company Nanologica has been awarded with the title Nanotech Company of the year. Nanologica received the award during SwedNanoTech’s Nano Forum in Stockholm.
The event was held on Wednesday May 15. The jury’s motivation for selecting Nanologica to receive the award reads:
“A company with roots in Swedish university research, with a clear mission and a smart and driven team that manages to solve customers’ problems through control of material properties at the nano-scale.”
The jury consisted of Anders Eliasson, Vice President Business Sweden, Åsalie Hartmanis, President SwedNanoTech, Björn O Nilsson, President of The Royal Swedish Academy of Engineering Sciences and Tord Lendau, Chairman CytaCoat AB.
“I am happy that the efforts of the Nanologica team have been recognized by a renowned body like SwedNanotech. It is rewarding that the jury appreciates our transformation from a research oriented university spin-out to a commercial company fanatically driven by market needs. Within drug delivery Nanologica´s materials provide a route to safer, more efficacious and affordable medicines for patients worldwide”, says CEO Andreas Bhagwani in a press release.
Nanologica develops nano-porous materials for use in drug delivery and chromatography. In March 2013, the company entered into an agreement with the Russian biotech company Nanolek for the reformulation of four drugs by encapsulating them in Nanologica’s porous silica particles. The company’s materials platform is based on micron-sized silica particles with nano-sized pores, which are engineered to meet specific properties. In drugs, their properties are used to control the release and uptake of active ingredients. Nanologica also develops innovative materials for chromatography.